Ask AI
ProCE Banner Activity

Two Drugs or Three? Slides for Navigating the Latest Evidence for Oral ART Initiation

Slideset

For decades, 3-drug regimens (3DRs) were considered the “gold standard” of antiretroviral therapy for HIV. However, numerous clinical trials and real-world studies demonstrated that modern 2-drug regimens (2DRs), both oral and long-acting injectable, are noninferior to 3DR alternatives. Download these slides to see practical frameworks and evidence to help you make confident, individualized decisions between 2- and 3-drug regimens when initiating antiretroviral therapy.

Released: September 15, 2026

Share

Provided by

ProCE Banner

Supporters

ViiV Healthcare

Target Audience

This program is intended for physicians (including HIV/infectious disease specialists, primary care physicians, and internists), nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the initiation of antiretroviral therapy in adults living with HIV.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate the clinical evidence, including results from VOGUE and other key trials and real-world studies, to make informed, evidence-based decisions about the comparative merits of 2DR and 3DR for ART initiation

  • Apply evidence-based clinical frameworks to select between 2DR and 3DR across a range of commonly encountered first-line ART scenarios, and communicate the rationale for 2DR confidently in shared decision-making conversations with patients

Financial Disclosures

Primary Author

Luis Buzón Martin, MD: consultant/advisor/speaker: ViiV.

Pedro Cahn, MD, PhD: consultant/advisor/speaker: ViiV; researcher: Gilead, MSD.

Charlotte-Paige Rolle, MD, MPH: consultant/advisor/speaker: Gilead, Theratechnologies, ViiV; researcher: Gilead, MSD, ViiV.